Immuneering Corporation IMRX

4.27 (0.07) (1.61%) as of 25 Sep
Market cap
$280.8M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
23.84 17.16 31.50 18.47
Current Ratio
24.00 17.50 32.45 19.47
Net Debt/EBITDA
14.96 12.58 10.07 7.73
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.80 0.85 1.37 0.96
Capex/Depreciation
(0.04) (7.33) 0.36 0.07
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.03 0.03 0.03 0.03
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.30) (0.22) (0.29) (0.26)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.30) (0.23) (0.29) (0.26)
Cash per Share
5.74 3.93 2.42 2.32
Shareholders Equity per Share
5.75 4.96 3.19 2.95
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
5.75 4.96 3.19 2.95
Free Cash Flow
(11.98) (9.96) (18.51) (16.53)
Working Capital
219.56 166.17 156.43 149.87
Capital Expenditures
(0.01) (0.12) (0.08) (0.03)
Net Current Asset Value
216.02 162.75 153.12 146.67
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Payables
1.77 1.75 1.38 2.89
Average Assets
154.81 142.35 132.75 121.06
Average Common Equity
142.85 129.94 124.18 109.84

Fold the line items

Columns are period end dates